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Abstract
The main haematological manifestations
seen in patients with antiphospholipid
antibodies (aPL) are thrombocytopenia,
usually mild, and haemolytic anaemia
with a positive Coombs test. Owing to the
shared characteristics with idiopathic
thrombocytopenic purpura, similar rules
are followed in the treatment of these
cytopenias. Two patients with severe aPL
associated cytopenias, who required
splenectomy after being refractory to
steroids, immunosuppressive agents, and
other treatments (intravenous gamma-
globulin, danazol), are described, and
previously reported cases are reviewed.
(Ann Rheum Dis 2000;59:920–923)
The antiphospholipid syndrome (APS) is char-
acterised by arterial/venous thrombosis, recur-
rent pregnancy loss, or thrombocytopenia in the
presence of antiphospholipid antibodies (aPL).1
These antibodies are identified as lupus anti-
coagulant, which prolongs phospholipid de-
pendent coagulation tests, or as anticardiolipin
antibodies (aCL) detected by immunoassays.
This entity, first described by Hughes in 1983 in
patients with systemic lupus erythematosus
(SLE),2 may appear in patients with no under-
lying disease—the “primary” APS.3
There are well documented associations
between aPL and abnormalities of specific cel-
lular components of the blood, such as throm-
bocytopenia, haemolytic anaemia, and, less
commonly, leucopenia.4 Thrombocytopenia is
usually mild and benign (70–120×109/l), rarely
associated with bleeding complications, and,
generally, does not require treatment. Moreo-
ver, some authors have shown that haemolytic
anaemia and Coombs positivity is also associ-
ated with aPL,4 and in some patients with pri-
mary APS, both thrombocytopenia and
haemolytic anaemia may occur together.
We describe two patients with severe aPL
associated cytopenias (haemolytic anaemia and
thrombocytopenia) who required splenectomy
after being refractory to steroids and immuno-
suppressive treatment, and review cases previ-
ously reported.
Case reports
CASE 1
A 49 year old woman was admitted to our hos-
pital in August 1987 with cutaneous purpura
on the legs and spontaneous mouth bleeding.
There was no previous history of thrombotic
events or obstetric complications. Laboratory
measurements showed a platelet count below
10×109/l and a normochromic anaemia (haemo-
globin 100 g/l) with a positive Coombs test and
a raised reticulocyte count. An immunological
profile showed negative antinuclear antibodies.
A bone marrow biopsy showed normal cellular-
ity with an increased megakaryocyte count.
The patient was diagnosed as having Evans’
syndrome, and treatment with prednisone (1
mg/kg/d) was started with an initial increase in
the haematological values. In May 1992 the
patient presented an acute respiratory infec-
tion, and the platelet count began to fall below
50×109/l and the haemoglobin value under 80
g/l. High positive (+++) aCL of the IgM
isotype were detected, and lupus anticoagulant
was absent. Subsequently, the patient required
several readmissions, most due to gastrointesti-
nal or respiratory infections, with a coinciden-
tal severe decrease of the haemoglobin value
and platelet count, and IgM aCL remained
positive at high titre (+++). During this time
the patient received diVerent treatments with
high doses of steroids, immunosuppressive
treatments (oral cyclophosphamide 50 mg/d,
azathioprine 100 mg/d), and danazol, without
response. In April 1995 the first dose of intra-
venous gammaglobulin was given. A total of
five doses were given until June 1997, without
response. Finally, splenectomy was performed
in January 1998, with previous prophylactic
antibiotics and vaccination, without postopera-
tive complications. After splenectomy, the hae-
moglobin stabilised above 120 g/l and the
platelet count above 500 × 109/l. Two years
later, the patient is doing well without haemor-
rhagic manifestations and with a normal
haemoglobin value and platelet count (fig 1).
CASE 2
The patient, a 32 year old woman, was admit-
ted to our hospital because of haemolytic anae-
mia and thrombocytopenia that could not be
controlled with drugs. When she was 30 the
patient had presented polyarthralgias and
spontaneous smouth bleeding. The laboratory
variables showed leucopenia (2×109/l), normo-
chromic anaemia (haemoglobin 90 g/l) with a
positive Coombs test and a platelet count of
15×109/l. An immunological profile showed
positive antinuclear antibodies (at a titre of
1/320), hypocomplementaemia (C4 levels
below 0.07) and positive IgG and IgM aCL at
high titre (+++). Anti-dsDNA and antibodies
to extractable nuclear antigens were negative.
The patient was diagnosed as having a
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lupus-like syndrome, and treatment with pred-
nisone (1 mg/kg/d) was started, with an initial
increase in the haematological values. Subse-
quently, she developed several complications
related to corticosteroid treatment—namely,
diabetes mellitus, Cushing’s syndrome, and
osteoporosis—and the haematological values
began to fall. Treatment with immunosuppres-
sive drugs (oral cyclophosphamide and aza-
thioprine), danazol, and intravenous gamma-
globulin was also added, without response.
Finally, splenectomy was performed in Decem-
ber 1998 and, one year later the patient has a
normal haemoglobin value and platelet count
without treatment.
Discussion
The main haematological manifestations seen
in patients with aPL are thrombocytopenia and
haemolytic anaemia. The co-occurrence of
Figure 1 Summary of the clinical and therapeutic course of patient 1. Ig = intravenous gammaglobulin; Aza =
azathioprine.
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Figure 2 Summary of the clinical and therapeutic course of patient 2. Ig = intravenous gammaglobulin.
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both immune mediated cytopenias was origi-
nally described by Evans in 1949.5 This strong
association of thrombocytopenia and haemo-
lytic anaemia suggests the possibility of a com-
mon mechanism of increased cellular destruc-
tion. Antibodies are thought to bind to the
surface of the platelets and erythrocytes and fix
complement, and the resulting cellular im-
mune complex is destroyed by the fixed
macrophages of the reticuloendothelial system.
There has been increasing interest in recent
years in the precise nature of the antigenic tar-
gets to which aPL bind platelets or erythro-
cytes, or both.6–8
Thrombocytopenia appears in about one
third of the patients with aPL. Cuadrado et al
reported a prevalence of 23% in a series of 171
patients with APS, being severe (<50×109/l)
only in six of them (18%).9 Rarely, this disorder
requires treatment and, owing to shared
characteristics with idiopathic thrombocyto-
penic purpura, similar treatment could be
followed—that is, high dose corticosteroids,
immunosuppressive or immunomodulating
agents, and intravenous immunoglobulin treat-
ment. When steroids or immunosuppressive
agents are unsuccessful, splenectomy is usually
performed to remove the major site of platelet
destruction and antibody production. There is
improvement in 70–90% of patients after
splenectomy, and platelets are permanently
restored to normal levels in at least two thirds
of patients.10 Unfortunately, there are no clini-
cal or analytical variables that adequately
predict the response to splenectomy. Only the
intensity of bleeding, age, and the immediate
postoperative peak platelet count are weak pre-
dictors of outcome.11
Some authors have analysed the relation
between the isotype of aCL and haemocyto-
penias and found a significant association
between IgM aCL and haemolytic anaemia.12–14
Furthermore, a prospective study showed that
the presence of IgM aCL is associated with the
development of haemolytic anaemia in patients
with SLE.15 Recommendations for the manage-
ment of immune mediated haemolytic anaemia
associated with high titre aPL are similar to
those for immune mediated thrombo-
cytopenia.4
Previous experience of the value of splenec-
tomy in the treatment of aPL associated
cytopenias is limited (table 1).16–21 In 1995 Bal-
lerini et al described the first case, a patient
with primary APS and severe thrombocyto-
penia treated unsuccessfully with steroids, who
was finally treated with splenectomy, with a
sustained and complete remission.18 More
recently, two studies have focused on the
response to splenectomy in patients with APS
and refractory thrombocytopenia. Hakim et al
reviewed the outcome of splenectomy in 12
patients with severe thrombocytopenia, three
of them with primary APS.19 After splenec-
tomy, complete remission of the thrombocyto-
penia occurred. There were no complications
from the splenectomy, and the patients who
received this treatment within one year of diag-
nosis of thrombocytopenia seemed to respond
well. In another recent study Galindo et al ana-
lysed 55 patients with APS with thrombocyto-
penia (<100×109/l) and reported that splenec-
tomy was required in 11 (20%) patients, nine
with an APS associated with SLE and the other
two with a primary APS.20 Postoperative com-
plications were not reported in any patient, and
all but two were responsive to splenectomy.
The results obtained in the patients published,
including our patients, support the usefulness
of splenectomy in the treatment of refractory
cytopenias associated with aPL, with a high
rate of response after the follow up and no
postoperative complications.
In conclusion, patients with aPL related
haemocytopenias (thrombocytopenia or
haemolytic anaemia, or both) often gain long
term remission of refractory cytopenias after
splenectomy, without exacerbation of their pri-
mary disease. Modern surgical techniques and
the use of prophylactic antibiotics and vaccina-
Table 1 Splenectomy in patients with refractory aPL associated cytopenias: reported cases
Case Author (date) Diagnosis aPL Age/sex Cytopenia Outcome
Current
treatment
1 Ballerini et al (1995)18 PAPS IgG 23/F Thromb CR —
2 Leuzzi et al (1997)17 PAPS IgG, IgM 35/F Thromb CR —
3 Leuzzi et al (1997)17 PAPS IgG, IgM 33/F Thromb CR —
4 Hakim et al (1998)19 PAPS IgG 39/F Thromb CR —
5 Hakim et al (1998)19 PAPS IgG 23/F Thromb CR —
6 Hakim et al (1998)19 PAPS IgG 40/F Thromb CR —
7 Hakim et al (1998)19 SLE IgG 37/F Thromb CR Pred, HCQ
8 Hakim et al (1998)19 SLE IgG 28/F Thromb CR Pred, MTX
9 Hakim et al (1998)19 SLE IgG 40/F Thromb CR Pred, AZA
10 Galindo et al (1999)20 SLE IgM 30/F Thromb CR Pred, HCQ
11 Galindo et al (1999)20 SLE LA 41/F Thromb CR Pred, HCQ
12 Galindo et al (1999)20 SLE LA, IgG 25/F Thromb CR Pred, HCQ
13 Galindo et al (1999)20 SLE LA, IgG, IgM 36/F Thromb CR Pred, AZA
14 Galindo et al (1999)20 SLE LA 58/F Thromb CR Pred
15 Galindo et al (1999)20 PAPS LA, IgG, IgM 35/F Thromb, HA CR Pred
16 Galindo et al (1999)20 SLE IgG 47/F Thromb CR HCQ
17 Galindo et al (1999)20 SLE IgG, IgM 22/F Thromb CR Pred, CQ
18 Galindo et al (1999)20 SLE LA, IgG, IgM 36/F Thromb, HA CR Pred
19 Galindo et al (1999)20 PAPS LA 47/M Thromb PR Pred
20 Galindo et al (1998)20 SLE LA, IgG 52/F Thromb PR HCQ
21 Present study PAPS IgM 60/F Thromb, HA CR —
22 Present study LLD IgG, IgM 32/F Thromb, HA CR —
aPL= antiphospholipid antibodies; PAPS = primary antiphospholipid syndrome; SLE = systemic lupus erythematosus; LLD =
lupus-like disease; LA = lupus anticoagulant; F = female; M = male; Thromb = thrombocytopenia; HA = haemolytic anaemia; CR
= complete remission; PR = partial remission; Pred = prednisone; HCQ = hydroxychloroquine; MTX = methotrexate; AZA = aza-
thioprine; CQ = chloroquine.
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tion have made splenectomy a safer option in
patients who do not respond to classic
treatments, such as corticosteroids.
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